Florida Cancer Specialists & Research Institute introduces liquid biopsy test
This test may be used to evaluate colorectal, lung, prostate, breast, and blood cancers.
Liquid biopsy represents an advancement in cancer diagnosis and treatment, utilising a simple draw of blood to test for circulating tumour DNA (ctDNA).
The introduction of liquid biopsy at FCS underscores the practice's focus on expanding its comprehensive genomic testing offerings, thereby improving diagnostic accuracy, guiding physicians in treatment decisions, and the patients' clinical outcomes.
FCS claims to have broadened its testing options for the 250 physicians serving more than 102,000 individuals across Florida, since the introduction of next-generation sequencing (NGS) offerings at its centralised in-house laboratory in 2021.
The practice has seen over 4.2 million annual visits and recently surpassed over 16,000 molecular tests processed at its Fort Myers lab facility.
FCS genetics laboratory associate director Jennifer Gass said: 'Liquid biopsy is especially effective for providing genetic information quickly for various types of advanced cancers to help physicians assess and better target treatments that may work best and monitor patient response.
'Additionally, because it is minimally invasive and easy to repeat on an ongoing basis, liquid biopsy is significantly more comfortable for patients.'
The expansion of the NGS testing menu at the FCS includes the addition of homologous recombination deficiency (HRD) testing, which analyses tumour DNA to determine potential treatment responses to poly (ADP-ribose) polymerase (PARP) inhibitors.
This class of drugs specifically targets cancer cells.
Other additions include a small heme NGS panel that identifies mutations related to myeloproliferative neoplasms and a quantitative assay for monitoring BCR-ABL gene fusions post-treatment in specific blood cancers.
"Florida Cancer Specialists & Research Institute introduces liquid biopsy test" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Thermo Fisher Scientific Introduces the Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System to Help Advance the Future of Precision Medicine
CARLSBAD, Calif.--(BUSINESS WIRE)--Today, Thermo Fisher Scientific announced that the Oncomine™ Comprehensive Assay Plus* is now available on the Ion Torrent™ Genexus™ System* helping accelerate precision oncology research. The Oncomine Comprehensive Assay Plus detects a broad range of genomic alterations in 517 genes and will now be able to deliver comprehensive genomic profiling (CGP) results as soon as the next day, enabled by Ion Torrent technology and easy, automated workflows. CGP facilitates the simultaneous analysis of a broad range of biomarkers in one test to maximize insights on the underlying oncogenic drivers in a timely manner. Already available on the Ion GeneStudio™ S5 systems*, the Oncomine Comprehensive Assay Plus detects single-nucleotide variants, insertions and deletions, copy number variations, and fusions. Additionally, the assay detects genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB) and microsatellite instability (MSI). With the capabilities of the Genexus System, researchers can now detect a broad range of these important biomarkers, quickly and easily. 'We have been waiting for this complete and rapid CGP solution that includes all the relevant biomarkers including TMB, MSI and HRD,' said Hector M Alcaraz, MS, Founder of Imagene Health, SA de CV, an early access user of the Oncomine Comprehensive Assay Plus on the Genexus System. 'This will make CGP more accessible to our local markets so that we can drive the future of precision medicine forward.' The Genexus System is an automated and integrated NGS platform capable of delivering NGS results as soon as the next day. With end-to-end automation that requires less hands-on time, the Genexus System makes genomic profiling accessible to more researchers with varying levels of experience. Now, with the Oncomine Comprehensive Assay Plus available on the Genexus System, research teams can leverage this end-to-end solution to deliver accurate and robust CGP results as soon as the next day. 'In recent years, new genomic insights have played an essential role in advancing our understanding of human health and driving novel drug development,' said Kathy Davy, president of Clinical Next Generation Sequencing at Thermo Fisher Scientific. 'The addition of the Oncomine Comprehensive Assay Plus on the Genexus System brings the benefits of rapid CGP to more labs, empowering researchers to leverage more comprehensive results at a much faster pace and accelerate what could be life-saving research.' For more information about the Oncomine Comprehensive Assay Plus on the Genexus System and how this is enabling research labs to accelerate oncology research, please visit *For Research Use Only. Not for use in diagnostic procedures. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit
Yahoo
5 days ago
- Yahoo
Pfizer and Astellas' Xtandi improves OS as combination therapy
Pfizer and Astellas' Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC), but only as a combination therapy. First approved in 2012, the prostate cancer therapy met the secondary endpoint of OS in the Phase III EMBARK trial (NCT02319837) when combined with leuprolide, compared to placebo plus leuprolide, in patients with nmHSPC with biochemical recurrence (BCR) and high risk for metastasis. Despite this, while a favourable trend was observed, there was no statistical significance between Xtandi monotherapy and placebo or leuprolide. In the trial, patients were randomised across three arms: Xtandi plus leuprolide, placebo plus leuprolide, or Xtandi alone. This update comes two years after the companies announced the trial met its primary endpoint with a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) for patients treated with Xtandi plus leuprolide versus placebo plus leuprolide. Although Pfizer and Astellas have not yet disclosed additional details about the OS data, they stated that full results will be presented at an upcoming medical meeting. They also noted that safety results were consistent with the known safety profile of Xtandi. Carolina Urologic Research Center's medical director Dr Neal Shore said: 'These data demonstrate that treatment with Xtandi can extend life for men with nmHSPC and high-risk BCR who have relapsed after initial curative-intent therapy with prostatectomy, radiation therapy or both, further validating EMBARK's metastasis-free survival (MFS) data. "While men with nmHSPC with high-risk BCR now have expanded treatment choices, these results demonstrate a clear clinical benefit, including both MFS and OS, supporting the clinical practice of initiating Xtandi for these patients.' Xtandi is currently approved in more than 80 countries, including the US, Europe and Japan. The US Food and Drug Administration (FDA) approved Xtandi for use in nmHSPC with high-risk BCR in November 2023, based on the EMBARK trial meeting its primary endpoint. The European Commission (EC) granted a label expansion for its use in the same patient population in April 2024. GlobalData predicts the prostate cancer market will be worth $22.62bn in 2030. Xtandi sales are set to start dropping due to the drug's patent expiring in 2026 in Europe and 2027 in the US. As a result, GlobalData predicts that sales of Xtandi will reach $5.59bn in 2025 and will drop to $2.24bn in 2030. The pharmaceutical industry is facing one of the most significant patent cliffs of the decade, with major companies preparing for substantial revenue losses, according to market analysts. A recent GlobalData report projects a sharp decline in the proportion of global drug sales protected by patents, with the figure expected to drop to just 4% by 2030. This compares to 12% in 2022 and 6% in 2024. GlobalData is the parent company of Clinical Trials Arena. "Pfizer and Astellas' Xtandi improves OS as combination therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Yahoo
Pfizer and Astellas' Xtandi improves OS as combination therapy
Pfizer and Astellas' Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC), but only as a combination therapy. First approved in 2012, the prostate cancer therapy met the secondary endpoint of OS in the Phase III EMBARK trial (NCT02319837) when combined with leuprolide, compared to placebo plus leuprolide, in patients with nmHSPC with biochemical recurrence (BCR) and high risk for metastasis. Despite this, while a favourable trend was observed, there was no statistical significance between Xtandi monotherapy and placebo or leuprolide. In the trial, patients were randomised across three arms: Xtandi plus leuprolide, placebo plus leuprolide, or Xtandi alone. This update comes two years after the companies announced the trial met its primary endpoint with a statistically significant and clinically meaningful improvement in metastasis-free survival (MFS) for patients treated with Xtandi plus leuprolide versus placebo plus leuprolide. Although Pfizer and Astellas have not yet disclosed additional details about the OS data, they stated that full results will be presented at an upcoming medical meeting. They also noted that safety results were consistent with the known safety profile of Xtandi. Carolina Urologic Research Center's medical director Dr Neal Shore said: 'These data demonstrate that treatment with Xtandi can extend life for men with nmHSPC and high-risk BCR who have relapsed after initial curative-intent therapy with prostatectomy, radiation therapy or both, further validating EMBARK's metastasis-free survival (MFS) data. "While men with nmHSPC with high-risk BCR now have expanded treatment choices, these results demonstrate a clear clinical benefit, including both MFS and OS, supporting the clinical practice of initiating Xtandi for these patients.' Xtandi is currently approved in more than 80 countries, including the US, Europe and Japan. The US Food and Drug Administration (FDA) approved Xtandi for use in nmHSPC with high-risk BCR in November 2023, based on the EMBARK trial meeting its primary endpoint. The European Commission (EC) granted a label expansion for its use in the same patient population in April 2024. GlobalData predicts the prostate cancer market will be worth $22.62bn in 2030. Xtandi sales are set to start dropping due to the drug's patent expiring in 2026 in Europe and 2027 in the US. As a result, GlobalData predicts that sales of Xtandi will reach $5.59bn in 2025 and will drop to $2.24bn in 2030. The pharmaceutical industry is facing one of the most significant patent cliffs of the decade, with major companies preparing for substantial revenue losses, according to market analysts. A recent GlobalData report projects a sharp decline in the proportion of global drug sales protected by patents, with the figure expected to drop to just 4% by 2030. This compares to 12% in 2022 and 6% in 2024. GlobalData is the parent company of Clinical Trials Arena. "Pfizer and Astellas' Xtandi improves OS as combination therapy" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
